Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

The Power of 3D Liver Culture Models for More Predictive and Insightful DMPK Studies

Published: Tuesday, December 03, 2013
Last Updated: Tuesday, December 03, 2013
Bookmark and Share
LiverChip™ enables robust and reproducible prediction of metabolic clearance in humans and provides extended time course for the study of low clearance compounds.

Zyoxel announces preliminary results from a testing by Sanofi on Zyoxel’s LiverChip™ platform for drug metabolism and pharmacokinetic (DMPK) studies. Sanofi employed a variety of morphological, genetic and functional analyses to fully characterise the LiverChip™ system, the full findings of which will be presented as part of Zyoxel’s In Vitro Liver Technology Symposium taking place on December 10, 2013 in Oxford, UK.

Under the terms of an Equipment Hire Agreement, Sanofi, an integrated global healthcare leader, has been exploring the utility of Zyoxel’s LiverChip™ platform. During the project, which commenced in December 2012 and involved the installation of a LiverChip™ device at a Sanofi research site, the company tested the human hepatocyte LiverChip™ system against current industry gold standard 2D plated cultures of primary hepatocytes. 

Using LiverChip™, Sanofi’s researchers were able to perform in depth DMPK analyses over much longer time courses of up to 6 days, including the accurate monitoring of dose clearance by the cytochrome P450 enzyme superfamily (CYPs), as well as the induction of CYP isoforms during drug metabolism. The study also confirmed that LiverChip™ does not suffer from any non-specific drug binding, while the results exhibited good reproducibility, both within individual plates and between replicate experiments. 

Extending the duration of cell culture increases pharmaceutical value and relevance 
As Dr. Emma Sceats, Chief Operating Officer of Zyoxel, summarised: “Sanofi have been a very good partner and customer of Zyoxel, and are one of an increasing number of international pharmaceutical companies we are working with. The value proposition of LiverChip’s™ extended time window is proving especially useful for applications such as assessing low clearance compounds, formation and detection of rare metabolites and to study the impact of chronic multiple dosing. We believe that the system can become part of the routine process for pre-clinical drug testing, ensuring only high quality candidates are taken through to clinical trials. Ultimately, we hope this will facilitate the production of more effective medicines that exhibit fewer side effects, enhancing the future treatment of patients.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Batten Disease may Benefit from Gene Therapy
NIH-funded animal study suggests one-shot approach to injecting genes.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Molecule Proves Key to Brain Repair After Stroke
Scientists found that a molecule known as growth and differentiation factor 10 (GDF10) plays a key role in repair mechanisms following stroke.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos